EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19

NCT04960202 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

2091

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: PF-07321332
DRUG: Ritonavir
DRUG: Placebo

Sponsor

Pfizer